Actionable Genomic Data Provided at the Point of Care
November 30, 2016
BELLEVUE, Wash.–(BUSINESS WIRE)–Translational Software®, Inc. (TSI), a leader in the intelligent use of genetic data for clinical decision support, today announced the company has been selected by DrFirst, a pioneer in electronic prescribing and medication management solutions, to enable pharmacogenomics (PGx)-based e-prescribing within the Rcopia® medication management system at the point of care.
The partnership will offer Rcopia’s 330+ electronic health record and hospital information system vendors and 62,000 providers a comprehensive solution for prescribing safer and more effective medications based on a patient’s genetic makeup.
TSI’s proprietary knowledge platform and Application Programming Interface (API) will provide genotyping prompts, genomic decision support and critical alerts regarding drug efficacy, toxicity and known interactions within the e-prescribing workflow to guide clinical decision making, minimize adverse reactions and enable physicians to prescribe the most effective medications in real-time. The PGx results can be used throughout the patient’s lifetime to improve treatment decisions and overall population health outcomes. Ordering and reporting will be delivered through Rcopia’s medication adherence tool, Patient Advisor℠.
“Integrating Translational Software’s PGx knowledge base within our e-prescribing platform allows us to deliver an in-workflow, evidence-based approach to medication prescribing that can be used as part of routine care,” stated G. Cameron Deemer, president of DrFirst. “In addition, the API will allow us to cost-effectively scale our efforts and develop a customized, seamless clinician experience for accessing genomic data within Rcopia.”
Developed using the Fast Healthcare Interoperability Resources (FHIR) specification, the API will enable Rcopia’s extensive user base to:
Identify patients as candidates for genotyping based on the medication being prescribed
Order recommended PGx tests through Exceltox and Alpha Genomix laboratories
Review detailed reports that identify potential drug-gene and drug-drug interactions and adverse events, and provide medication alternatives
Access genetic test results to flag interactions for future medications over the patient’s lifetime
DrFirst’s Rcopia is the leading platform for drug e-prescribing and controlled substance e-prescribing, electronic prior authorization, medication history and medication adherence. It is also the first system in the industry to provide real-time benefit checking to guide cost-effective prescription decisions.
“We have a significant opportunity to drive value-based healthcare throughout the U.S. by eliminating costly and ineffective therapies through use of a genomic e-medication management system at such a large scale,” stated Don Rule, CEO, TSI. “We are very excited to be working with DrFirst to develop an IT infrastructure that makes it possible to improve treatment decisions by providing timely, accessible and actionable genomic information to clinicians as part of their existing workflow.”
TSI’s PGx knowledge base and genomic decision support is expected to be available in Rcopia in the first quarter of 2017.
DrFirst pioneers technology solutions that inform the doctor-patient point of encounter, optimizing provider access to patient information, enhancing the doctor’s clinical view of the patient, and improving care delivery and clinical outcomes. Our growth is driven by a commitment to innovation, security, and reliability across a wide array of services, including Medication Management, Medication Adherence, and Secure Communication and Collaboration. We are proud of our track record of service to more than 330 EMR/EHR/HIS vendors and an extensive network of providers, hospitals and patients. For more information, please visit www.drfirst.com. For media inquires, please contact Ellie Whims at 301-231-9510 ext. 2808 or firstname.lastname@example.org.
About Translational Software, Inc.
Translational Software provides end-to-end solutions to support laboratories and healthcare providers adopting personalized medicine. Its powerful PGx portal transforms genomic and molecular data into actionable knowledge, integrating the best available clinical decision support with laboratory and clinical information systems to guide therapeutic options for medication management to enhance patient care. For more information visit www.translationalsoftware.com or follow us on LinkedIn.
Translational Software, Inc.
Myla Wagner, 925-736-7515